Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Torus Biosystems is raising $25,214,240.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Shawn Marcell played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Torus Biosystems

Torus Biosystems is developing the next generation of POC molecular diagnostics for syndromic infectious diseases based on the novel integration of qPCR and microarray technologies that enable detection and quantification of DNA in under 30 minutes. The Synestia System employs the syndromic testing approach, which is faster and more accurate than conventional methods, and delivers rapid, comprehensive, sample-to-answer solutions at the patient point of care in a compact and portable system that supports decentralized healthcare settings. Torus Biosystems was spun out from the Wyss Institute for Biologically Inspired Engineering at Harvard University in 2020 to develop and commercialize the proprietary DNA/RNA detection technology developed by Wyss Core Faculty member, Peng Yin, PhD, Professor, Department of Systems Biology, Harvard Medical School, and Wyss Alumnus David Zhang, PhD, Associate Professor of Bioengineering, Rice University.

To learn more about Torus Biosystems, visit http://www.torus.bio/

Contact:
Shawn Marcell, President and Chief Executive Officer
617-921-4494
https://www.linkedin.com/in/shawn-marcell-3a542b4/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved